CiRA reports a summary of its iPS Cell Stock
The Facility for iPS Cell Therapy (FiT) at CiRA has published a paper in Inflammation and Regeneration on September 2 that describes the iPS Cell Stock it is manufacturing. This Stock consists of clinical-grade cells, including iPS cells, that have been used in multiple operations in Japan. The goal is to manufacture a stock that serves first the entire Japanese and eventually the whole global population. The paper goes on to describe FiT's goals and accomplishments.
- Journal: Inflammation and Regeneration
- Title: Overview of an iPS cell stock at CiRA
- Authors: Masafumi Umekage, Yoshiko Sato, Naoko Takasu
- Author Affiliations:
- Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan